Literature DB >> 393627

Physiological and metabolic alterations accompanying systemic candidiasis in mice.

R D Leunk, R J Moon.   

Abstract

Mice challenged intravenously with 10(6) viable Candida albicans died between 1 and 16 days after infection. Near the time of death, over 98% of the recoverable fungi came from the kidneys. Physiologically, animals were in renal failure near the time of death as evidenced by elevated blood urea nitrogen (BUN) and blood creatinine levels and a creatinine clearance rate which was about one-half normal. No abnormalities in liver glucogen and blood glucose levels were detectable. When mice were challenged with 4.5 X 10(6) viable C. albicans, they all died within 12 h. Near the time of death they had normal BUN values and were hyperglycemic. In mice receiving 4.5 X 10(6) heat-killed C. albicans, no deaths occurred and liver glycogen, blood glucose, and BUN levels all remained within a normal range and were different from responses to bacterial endotoxin. Cumulatively, the results demonstrate two distinct syndromes for the pathogenesis of experimental C. albicans infections. At the lower dose, mice were in renal failure associated with progressive renal infection. At the higher dose, renal failure was not observed. If a toxin was associated with death from the latter dose, it was not similar to bacterial endotoxin.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 393627      PMCID: PMC414724          DOI: 10.1128/iai.26.3.1035-1041.1979

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  A new simple semimicro method for colorimetric determination of urea.

Authors:  J J COULOMBE; L FAVREAU
Journal:  Clin Chem       Date:  1963-02       Impact factor: 8.327

2.  Experimental moniliasis in the guinea-pig.

Authors:  H I WINNER
Journal:  J Pathol Bacteriol       Date:  1960-04

3.  Pathogenicity of Candida.

Authors:  S MOURAD; L FRIEDMAN
Journal:  J Bacteriol       Date:  1961-04       Impact factor: 3.490

4.  The influence of cortisone on experimental fungus infections in mice.

Authors:  D B LOURIA; N FALLON; H G BROWNE
Journal:  J Clin Invest       Date:  1960-09       Impact factor: 14.808

5.  Fever from pathogenic fungi.

Authors:  A I BRAUDE; J McCONNELL; H DOUGLAS
Journal:  J Clin Invest       Date:  1960-08       Impact factor: 14.808

6.  An experimental approach to the study of infections by yeast-like organisms.

Authors:  H I WINNER
Journal:  Proc R Soc Med       Date:  1958-07

7.  Immunity in experimental moniliasis.

Authors:  H I WINNER
Journal:  J Pathol Bacteriol       Date:  1956-01

8.  Characteristics of Fungous Diseases.

Authors:  A T Henrici
Journal:  J Bacteriol       Date:  1940-02       Impact factor: 3.490

9.  CHARACTERIZATION OF THE PYROGENICITY OF CANDIDA ALBICANS, SACCHAROMYCES CEREVISIAE, AND CRYPTOCOCCUS NEOFORMANS.

Authors:  G S KOBAYASHI; L FRIEDMAN
Journal:  J Bacteriol       Date:  1964-09       Impact factor: 3.490

10.  Production in mice of tolerance to the toxic manifestations of Candida albicans.

Authors:  H F HASENCLEVER; W O MITCHELL
Journal:  J Bacteriol       Date:  1962-09       Impact factor: 3.490

View more
  10 in total

1.  High-dose ascorbate with low-dose amphotericin B attenuates severity of disease in a model of the reappearance of candidemia during sepsis in the mouse.

Authors:  Asada Leelahavanichkul; Poorichaya Somparn; Tanabodee Bootprapan; Hongbin Tu; Pattarin Tangtanatakul; Ratchanok Nuengjumnong; Navaporn Worasilchai; Khajohn Tiranathanagul; Somchai Eiam-ong; Mark Levine; Ariya Chinampon; Nattachai Srisawat
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-08-01       Impact factor: 3.619

2.  Mechanism underlying renal failure caused by pathogenic Candida albicans infection.

Authors:  Shin Jae-Chen; Jeon Young-Joo; Park Seon-Min; Seo Kang Seok; Shim Jung-Hyun; Chae Jung-Il
Journal:  Biomed Rep       Date:  2014-11-24

3.  Experimental pulmonary candidiasis.

Authors:  R T Sawyer
Journal:  Mycopathologia       Date:  1990-02       Impact factor: 2.574

4.  Influence of IgG Subclass on Human Antimannan Antibody-Mediated Resistance to Hematogenously Disseminated Candidiasis in Mice.

Authors:  Casey T Nishiya; Gayle M Boxx; Kerry Robison; Carol Itatani; Thomas R Kozel; Mason X Zhang
Journal:  Infect Immun       Date:  2015-11-16       Impact factor: 3.441

5.  Combined effect of fluconazole and recombinant human interleukin-1 on systemic candidiasis in neutropenic mice.

Authors:  B J Kullberg; J W van 't Wout; R J Poell; R van Furth
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

6.  UDP-glucose 4, 6-dehydratase activity plays an important role in maintaining cell wall integrity and virulence of Candida albicans.

Authors:  Manimala Sen; Bhavin Shah; Srabanti Rakshit; Vijender Singh; Bhavna Padmanabhan; Manikandan Ponnusamy; Koteppa Pari; Ram Vishwakarma; Dipankar Nandi; Parag P Sadhale
Journal:  PLoS Pathog       Date:  2011-11-17       Impact factor: 6.823

7.  The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney.

Authors:  Kritika Ramani; Abhishek V Garg; Chetan V Jawale; Heather R Conti; Natasha Whibley; Edwin K Jackson; Sruti S Shiva; William Horne; Jay K Kolls; Sarah L Gaffen; Partha S Biswas
Journal:  PLoS Pathog       Date:  2016-11-04       Impact factor: 6.823

8.  Pathogenic Effects of IFIT2 and Interferon-β during Fatal Systemic Candida albicans Infection.

Authors:  Marcin Stawowczyk; Shamoon Naseem; Valeria Montoya; Darren P Baker; James Konopka; Nancy C Reich
Journal:  MBio       Date:  2018-04-17       Impact factor: 7.867

9.  Massive induction of innate immune response to Candida albicans in the kidney in a murine intravenous challenge model.

Authors:  Donna M MacCallum
Journal:  FEMS Yeast Res       Date:  2009-10       Impact factor: 2.796

10.  Novel insights into disseminated candidiasis: pathogenesis research and clinical experience converge.

Authors:  Brad Spellberg
Journal:  PLoS Pathog       Date:  2008-02-08       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.